
## **Fraser Soares**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4300278/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nature Immunology, 2010, 11, 55-62.	14.5	1,125
2	Amino Acid Starvation Induced by Invasive Bacterial Pathogens Triggers an Innate Host Defense Program. Cell Host and Microbe, 2012, 11, 563-575.	11.0	331
3	Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019, 176, 831-843.e22.	28.9	317
4	NOD-Like Receptors: Versatile Cytosolic Sentinels. Physiological Reviews, 2015, 95, 149-178.	28.8	270
5	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through IncRNA PCAT19. Cell, 2018, 174, 564-575.e18.	28.9	264
6	Mitochondria in innate immunity. EMBO Reports, 2011, 12, 901-910.	4.5	222
7	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nature Cell Biology, 2021, 23, 87-98.	10.3	209
8	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	21,4	196
9	An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. Journal of Cell Science, 2009, 122, 3161-3168.	2.0	167
10	Shigella Induces Mitochondrial Dysfunction and Cell Death in Nonmyleoid Cells. Cell Host and Microbe, 2009, 5, 123-136.	11.0	140
11	Enhancement of Reactive Oxygen Species Production and Chlamydial Infection by the Mitochondrial Nod-like Family Member NLRX1. Journal of Biological Chemistry, 2010, 285, 41637-41645.	3.4	124
12	Refined RIP-seq protocol for epitranscriptome analysis with low input materials. PLoS Biology, 2018, 16, e2006092.	5.6	112
13	Transcriptional landscape of the human cell cycle. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3473-3478.	7.1	110
14	NLRX1 does not inhibit MAVS-dependent antiviral signalling. Innate Immunity, 2013, 19, 438-448.	2.4	73
15	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Research, 2017, 77, 5479-5490.	0.9	71
16	Peptidoglycan ld-Carboxypeptidase Pgp2 Influences Campylobacter jejuni Helical Cell Shape and Pathogenic Properties and Provides the Substrate for the dl-Carboxypeptidase Pgp1. Journal of Biological Chemistry, 2014, 289, 8007-8018.	3.4	69
17	The Mitochondrial Protein NLRX1 Controls the Balance between Extrinsic and Intrinsic Apoptosis. Journal of Biological Chemistry, 2014, 289, 19317-19330.	3.4	63
18	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications, 2020, 11, 441.	12.8	51

FRASER SOARES

#	Article	IF	CITATIONS
19	CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer. Oncogene, 2021, 40, 6601-6613.	5.9	37
20	The mitochondrial Nod-like receptor NLRX1 modifies apoptosis through SARM1. Molecular and Cellular Biochemistry, 2019, 453, 187-196.	3.1	33
21	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nature Communications, 2021, 12, 1781.	12.8	32
22	Post-transcriptional Inhibition of Luciferase Reporter Assays by the Nod-like Receptor Proteins NLRX1 and NLRC3. Journal of Biological Chemistry, 2012, 287, 28705-28716.	3.4	29
23	Mitochondrial protein import stress regulates the LC3 lipidation step of mitophagy through NLRX1 and RRBP1. Molecular Cell, 2022, 82, 2815-2831.e5.	9.7	25
24	CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy. Blood, 2021, 137, 2171-2181.	1.4	23
25	The Basis and Promise of Programmable RNA Editing and Modification. Frontiers in Genetics, 2022, 13, 834413.	2.3	13
26	Crucial role of noncoding RNA in driving prostate cancer development and progression. Epigenomics, 2017, 9, 1-3.	2.1	4
27	Noncoding RNA for personalized prostate cancer treatment: utilizing the â€~dark matters' of the genome. Personalized Medicine, 2017, 14, 159-169.	1.5	0